SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.930
-0.070 (-1.75%)
At close: Jun 22, 2026, 4:00 PM EDT
3.820
-0.110 (-2.80%)
Pre-market: Jun 23, 2026, 4:34 AM EDT

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
301178356330340
Market Cap Growth
1631.79%405.79%-44.53%113.51%-91.25%-
Enterprise Value
199.2987.4219.1112.8120.61304.84
Last Close Price
3.933.743.796.885.9078.10
PS Ratio
--26.6228.351.245.58
PB Ratio
1.311.181.361.110.96-
P/TBV Ratio
1.281.511.350.660.83-
P/OCF Ratio
-----170.94
EV/Sales Ratio
--14.455.720.865.01
Debt / Equity Ratio
0.020.030.160.090.17-
Net Debt / Equity Ratio
-0.44-0.60-0.62-0.88-0.29-
Net Debt / EBITDA Ratio
1.841.980.421.480.362.96
Net Debt / FCF Ratio
1.981.980.472.000.363.88
Asset Turnover
-00.020.030.360.88
Quick Ratio
11.069.132.615.231.371.80
Current Ratio
11.459.462.985.451.471.90
Return on Equity (ROE)
-0.21%14.96%-81.92%-95.51%-120.35%-
Return on Assets (ROA)
-27.62%-45.12%-66.98%-56.47%-43.74%-19.46%
Return on Invested Capital (ROIC)
-55.59%-104.24%-173.64%-130.37%-81.70%-35.65%
Return on Capital Employed (ROCE)
-29.04%-49.36%-78.49%-69.84%-63.84%-26.74%
Buyback Yield / Dilution
-227.56%-562.28%-67.74%-26.86%-59.20%-1.21%
Total Shareholder Return
-227.56%-562.28%-67.74%-26.86%-59.20%-1.21%
SEC Filings: 10-K · 10-Q